Calcium

Miror Bliss, a FemTech supplement, aims to support Indian women experiencing perimenopause and menopause, addressing common symptoms and promoting holistic health with 18 scientifically selected ingredients. The product targets hormonal imbalances, hot flashes, mood swings, and sleep disturbances, reflecting the growing demand for targeted wellness solutions in India.

A high-protein, high-fiber meal plan supports a healthy menopause transition, focusing on nutrients like protein, fiber, omega-3s, calcium, and magnesium. The 7-day plan includes modifications for 1,500 and 2,000 calories, emphasizing omega-3-rich foods to reduce symptoms and support hormone changes. Each day provides at least 80g of protein and 30g of fiber, with tips for balanced eating, gut health, inflammation reduction, and bone maintenance.

Cytokinetics initiates Phase 1 clinical study of CK-4015089 (CK-089), a fast skeletal muscle troponin activator, evaluating safety, tolerability, and pharmacokinetics in healthy participants. The study includes single and multiple ascending dose cohorts, each with 10 participants. Pre-clinical results show increased muscle force and function, suggesting potential applications in muscular dystrophy and other muscle function impairments.

Advances in microscopy and live-cell imaging are crucial for understanding dynamic cellular processes, moving beyond static imaging to observe real-time changes. This shift is essential for developing more accurate models of disease and drug discovery, with technologies like light sheet microscopy and genetically encoded calcium indicators enhancing our ability to study cellular behavior without harming cells. The industry is also transitioning from 2D to 3D cell cultures to better mimic in vivo conditions, and phenotypic screening is regaining importance as a method to identify first-in-class drugs. Label-free imaging and sophisticated software are further advancing live-cell analysis, enabling more detailed and less invasive studies.

Hennepin Healthcare seeks permission to enroll car crash victims in a clinical trial of two drugs reducing blood loss, aiming to determine if earlier treatment during transport improves survival rates. The study, part of the LITES Network, requires a federal exception for informed consent due to patients' unconsciousness or severe injury.

Hennepin Healthcare seeks permission to enroll car-crash victims in a clinical trial of two drugs reducing blood loss, aiming to determine if earlier treatment during transport improves survival rates. The study, part of the LITES Network, requires a federal exception for informed consent due to patient unconsciousness. Patients will receive either the drugs or a placebo, with outcomes assessed immediately and 30 days post-injury. The hospital seeks community feedback before final approval from oversight boards.

A multicenter, single-arm, open-label, phase Ib/II study conducted in China evaluated JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone (GCTB). The study, approved by ethics committees and registered at ClinicalTrials.gov (NCT04255576), involved 24 centers and administered JMT103 subcutaneously at 2 mg/kg every four weeks. Primary endpoints included histopathological or radiological objective tumor response (OTR), with secondary endpoints covering overall response rate (ORR), disease control rate (DCR), time to progression (TTP), and safety. Statistical analyses were performed using SAS software, with a sample size of 125 patients to ensure a 95% confidence interval for OTR.

Budget cuts have shifted nutrition research funding from government to private industries, leading to biases. Primary research, traditionally NIH-funded, is now less common. Applied research, often funded by pharma and food industries, can justify supplements or show harm in certain foods. Public health research, ideally government-funded, also sees private industry involvement. Clinical research, primarily pharma-funded, tests medications with variability complicating results. Pharmacological research focuses on managing health markers for long-term profitability. Bias in research includes funding bias, myth bias, scholarly pride bias, publication bias, media bias, government bias, and other conflicts of interest. Understanding these biases is crucial for scrutinizing research conclusions.

CDSCO's August 2024 drug alert flagged over 50 drugs as substandard, prompting manufacturers' protests. The CDSCO must expand its reach and enhance inspection rigor, while India's drug certification lacks inter-state networking. Ethical standards and a unified national framework are needed. Positive steps include CDSCO's digital regulatory system and plans for a material-to-patient infrastructure, aiming to emulate the European Medicines Agency's model.